Shuzo Hamamoto
Papers
3
Total Citations
46
H-Index
3
About
Dr. Shuzo Hamamoto is a leading urological surgeon and researcher whose work is transforming the surgical management of urinary tract stones and advancing novel therapies for prostate cancer. His most impactful contributions center on optimizing minimally invasive surgical techniques, particularly through pioneering comparative trials. Dr. Hamamoto’s landmark 2022 randomized clinical trial, which has garnered 33 citations, directly compared robotic-assisted fluoroscopic-guided renal access against traditional ultrasound guidance for percutaneous nephrolithotomy (PCNL). This study provided critical evidence on surgical outcomes, helping to define best practices for this complex procedure. He further demonstrated his commitment to improving patient safety through a large-scale, multicenter survey on complications and ureteral stricture rates following ureteroscopy with laser lithotripsy, a study that has already accumulated 9 citations and offers vital benchmarking data for the field. Beyond stone disease, Dr. Hamamoto is exploring innovative chemopreventive strategies, as evidenced by his 2025 preliminary study on the safety and efficacy of luteolin, a natural flavonoid, for prostate cancer patients under active surveillance. This forward-looking work highlights his dedication to expanding treatment options for prostate cancer. Through rigorous clinical trials and collaborative research, Dr. Hamamoto is shaping the future of urological care.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3